Back to newsRapport Therapeutics, Inc.: UBS cuts target price to $64 from $71RRAPP•2026-11-05UBS cut its target price for Rapport Therapeutics to $64 from $71.Related NewsKKimberly-Clark up after Q3 profit beats estimatesKMB•2026-11-05AApollo Global Management target price cut to $160 from $163APO•2026-11-05XUS upstream M&A value climbs to $12.6 billion in third quarter, Enverus saysXLE•2026-11-05ANasdaq halts AGLT trading for volatility at 9:34 a.m.AGLT•2026-11-05MAMEX trading halt; last price 3.710900MTSG•2026-11-05
RAPP•RAPP•RAPP•RAPP•
